Silence Therapeutics plc (SLN) Institutional Ownership

Ownership Summary

Silence Therapeutics plc (NASDAQ:SLN) showed up in the 13F filings of 54 institutional investors as of September 2025.

• These investors held 15.0% of outstanding shares in September 2025, up from 13.2% in June 2025.
• They increased total shares held in Silence Therapeutics by 15.52% from last quarter, and the number of investors in SLN stayed flat annually.
• Among the 54 funds, 22 bought more Silence Therapeutics shares, 15 sold down, and 17 held their ground.
• Altogether, these fund groups held 21.32Mn shares in SLN by September 2025, up by 2.86Mn shares quarter on quarter, and up 715.48K shares year over year.
• TCG Crossover Management, LLC leads ownership in SLN with 3.03Mn shares as of September 30, 2025, equal to 2.14% of outstanding shares.
• The biggest buyers of Silence Therapeutics for the quarter ending September 2025 included CITADEL ADVISORS LLC (990.75K), Nantahala Capital Management, LLC (604.3K), MILLENNIUM MANAGEMENT LLC (414.6K), Jones Hill Capital LP (301.6K), Tetragon Partners GP Ltd (264.79K).
• The largest sellers of Silence Therapeutics for the quarter ending September 2025 were Morgan Stanley (259.14K), HSBC HOLDINGS PLC (222.83K), Seven Fleet Capital Management LP (138.44K), Ishara Investments LP (99.5K), M28 Capital Management LP (83.9K).
• Per Business Quant data, the top 10 holders of Silence Therapeutics for the quarter ending September 2025 are TCG Crossover Management, LLC (3.03Mn), Siren, L.L.C. (2.91Mn), Redmile Group, LLC (2.16Mn), Nantahala Capital Management, LLC (2.15Mn), CITADEL ADVISORS LLC (1.23Mn), MILLENNIUM MANAGEMENT LLC (1.07Mn), GREAT POINT PARTNERS LLC (1.02Mn), Nextech Invest, Ltd. (952.4K), Ikarian Capital, LLC (865.78K), Tetragon Partners GP Ltd (630.16K).